Last reviewed · How we verify

prophylactic heparin

Matthew Neal MD · FDA-approved active Small molecule Under review Quality 0/100

prophylactic heparin is a Anticoagulant Small molecule drug developed by Matthew Neal MD. It is currently FDA-approved for Prophylaxis of venous thromboembolism in surgical patients, Prophylaxis of thromboembolism in medical patients at risk, Prevention of clotting in extracorporeal circulation. Also known as: enoxaparin, dalteparin, Tinzaparin, Fondparinux.

Prophylactic heparin inhibits blood clotting by enhancing the activity of antithrombin III, preventing thrombus formation.

Prophylactic heparin is used to study conditions such as anemia, sickle cell, acute chest syndrome, and acute exacerbation of COPD. It works by activating antithrombin-III, a protein that helps regulate blood clotting, through its oligosaccharide modality.

At a glance

Generic nameprophylactic heparin
Also known asenoxaparin, dalteparin, Tinzaparin, Fondparinux, Heparin
SponsorMatthew Neal MD
Drug classAnticoagulant
TargetAntithrombin III (indirect); Factors IIa and Xa
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Heparin is an anticoagulant that potentiates antithrombin III, a natural inhibitor of several blood coagulation factors (particularly factors IIa and Xa). By accelerating the inactivation of these clotting factors, heparin reduces the formation of fibrin clots and prevents thromboembolism. When used prophylactically, it is administered at lower doses to prevent clot formation in high-risk patients without causing therapeutic anticoagulation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about prophylactic heparin

What is prophylactic heparin?

prophylactic heparin is a Anticoagulant drug developed by Matthew Neal MD, indicated for Prophylaxis of venous thromboembolism in surgical patients, Prophylaxis of thromboembolism in medical patients at risk, Prevention of clotting in extracorporeal circulation.

How does prophylactic heparin work?

Prophylactic heparin inhibits blood clotting by enhancing the activity of antithrombin III, preventing thrombus formation.

What is prophylactic heparin used for?

prophylactic heparin is indicated for Prophylaxis of venous thromboembolism in surgical patients, Prophylaxis of thromboembolism in medical patients at risk, Prevention of clotting in extracorporeal circulation.

Who makes prophylactic heparin?

prophylactic heparin is developed and marketed by Matthew Neal MD (see full Matthew Neal MD pipeline at /company/matthew-neal-md).

Is prophylactic heparin also known as anything else?

prophylactic heparin is also known as enoxaparin, dalteparin, Tinzaparin, Fondparinux, Heparin.

What drug class is prophylactic heparin in?

prophylactic heparin belongs to the Anticoagulant class. See all Anticoagulant drugs at /class/anticoagulant.

What development phase is prophylactic heparin in?

prophylactic heparin is FDA-approved (marketed).

What are the side effects of prophylactic heparin?

Common side effects of prophylactic heparin include Bleeding, Heparin-induced thrombocytopenia (HIT), Thrombosis, Injection site reactions, Osteoporosis (with prolonged use).

What does prophylactic heparin target?

prophylactic heparin targets Antithrombin III (indirect); Factors IIa and Xa and is a Anticoagulant.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing